Clinical and Patient-Reported Outcomes After Mix-and-Match Implantation of a Trifocal and Non-Diffractive Extended Depth of Focus IOL.

Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2025-08-09 eCollection Date: 2025-01-01 DOI:10.2147/OPTH.S533091
Irene S Zhou, Dagny C Zhu
{"title":"Clinical and Patient-Reported Outcomes After Mix-and-Match Implantation of a Trifocal and Non-Diffractive Extended Depth of Focus IOL.","authors":"Irene S Zhou, Dagny C Zhu","doi":"10.2147/OPTH.S533091","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate cataract surgery outcomes following mix-and-match implantation of a trifocal and extended-depth-of-focus (EDOF) intraocular lens (IOL).</p><p><strong>Setting: </strong>Single center, private practice.</p><p><strong>Design: </strong>Single arm, non-interventional, ambispective study.</p><p><strong>Methods: </strong>Patients who underwent femtosecond-laser assisted cataract surgery with mix-and-match implantation of the Clareon PanOptix trifocal IOL in the non-dominant eye and Clareon Vivity EDOF IOL in the dominant eye from September 2022 to November 2023 were reviewed. Only healthy eyes with postoperative absolute spherical equivalent (SE) ≤ 0.50 diopters (D) and cylinder ≤ 0.75 D were included. At 3 months postoperatively, binocular corrected and uncorrected visual acuity at distance (CDVA and UDVA), intermediate (DCIVA and UIVA), and near (DCNVA and UNVA) along with patient-reported outcomes (QUVID and IOLSAT questionnaires) were assessed.</p><p><strong>Results: </strong>100 eyes of 50 patients were included. Postoperatively, the mean binocular CDVA and UDVA was -0.08 ± 0.05 logMAR and -0.06 ± 0.05 logMAR, respectively. Overall, 100%, 98%, and 90% of patients achieved binocular UDVA, UIVA, and UNVA of 20/25 or better, respectively. Eighty-four percent of patients reported complete spectacle independence. Few patients were \"bothered very much\" by haloes, glare, or starbursts (0-4%). No patients reported dissatisfaction with their vision. Overall, 94% and 92% of patients would elect the same IOLs and recommend the same procedure to friends and family, respectively.</p><p><strong>Conclusion: </strong>Mix-and-match implantation of the Clareon PanOptix and Vivity IOLs yields good patient satisfaction potentially by combining the advantages of each lens resulting in a high degree of satisfaction and low rates of visual disturbances.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2625-2635"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12345935/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ophthalmology (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OPTH.S533091","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To evaluate cataract surgery outcomes following mix-and-match implantation of a trifocal and extended-depth-of-focus (EDOF) intraocular lens (IOL).

Setting: Single center, private practice.

Design: Single arm, non-interventional, ambispective study.

Methods: Patients who underwent femtosecond-laser assisted cataract surgery with mix-and-match implantation of the Clareon PanOptix trifocal IOL in the non-dominant eye and Clareon Vivity EDOF IOL in the dominant eye from September 2022 to November 2023 were reviewed. Only healthy eyes with postoperative absolute spherical equivalent (SE) ≤ 0.50 diopters (D) and cylinder ≤ 0.75 D were included. At 3 months postoperatively, binocular corrected and uncorrected visual acuity at distance (CDVA and UDVA), intermediate (DCIVA and UIVA), and near (DCNVA and UNVA) along with patient-reported outcomes (QUVID and IOLSAT questionnaires) were assessed.

Results: 100 eyes of 50 patients were included. Postoperatively, the mean binocular CDVA and UDVA was -0.08 ± 0.05 logMAR and -0.06 ± 0.05 logMAR, respectively. Overall, 100%, 98%, and 90% of patients achieved binocular UDVA, UIVA, and UNVA of 20/25 or better, respectively. Eighty-four percent of patients reported complete spectacle independence. Few patients were "bothered very much" by haloes, glare, or starbursts (0-4%). No patients reported dissatisfaction with their vision. Overall, 94% and 92% of patients would elect the same IOLs and recommend the same procedure to friends and family, respectively.

Conclusion: Mix-and-match implantation of the Clareon PanOptix and Vivity IOLs yields good patient satisfaction potentially by combining the advantages of each lens resulting in a high degree of satisfaction and low rates of visual disturbances.

Abstract Image

Abstract Image

混合配型三焦无衍射扩展焦深度人工晶体植入术后的临床和患者报告结果。
目的:评价混合配型三焦扩展焦深度人工晶状体植入术后的白内障手术效果。设置:单中心,私人执业。设计:单组、非干预性、双视角研究。方法:回顾性分析2022年9月至2023年11月行飞秒激光辅助白内障手术,非优势眼混合配型植入Clareon PanOptix三焦人工晶体,优势眼混合配型植入Clareon Vivity EDOF人工晶体的患者。仅纳入术后绝对球等效(SE)≤0.50屈光度(D)和柱体≤0.75 D的健康眼。术后3个月,对双眼矫正视力和未矫正视力进行远距离(CDVA和UDVA)、中度(DCIVA和UIVA)和近距离(DCNVA和UNVA)以及患者报告的结果(QUVID和IOLSAT问卷)进行评估。结果:纳入50例患者100只眼。术后双眼平均CDVA和UDVA分别为-0.08±0.05 logMAR和-0.06±0.05 logMAR。总体而言,100%、98%和90%的患者双眼UDVA、uva和UNVA分别达到20/25或更好。84%的患者报告完全独立佩戴眼镜。很少有患者对光晕、眩光或星暴“非常困扰”(0-4%)。没有患者报告对视力不满意。总的来说,94%和92%的患者分别会选择相同的人工晶状体,并向朋友和家人推荐相同的手术。结论:Clareon PanOptix和Vivity人工晶状体混合配型植入术,结合了两种晶状体的优点,患者满意度高,视力障碍率低,有可能获得良好的患者满意度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信